E-Medicare Pharma
Online Medicine Pharmacy
Ruxonib (Ruxolitinib) 1.5% is a topical medication primarily used in the treatment of certain skin conditions, particularly moderate to severe atopic dermatitis (eczema). It belongs to a class of drugs known as Janus kinase (JAK) inhibitors, which work by blocking the activity of enzymes involved in inflammation and immune response. Ruxonib 1.5% offers a targeted therapy option for patients with atopic dermatitis, helping to reduce inflammation and improve skin symptoms.
1. Indications:
Ruxonib (Ruxolitinib) 1.5% is indicated for the treatment of:
2. Pharmacology:
Ruxonib (Ruxolitinib) 1.5% exerts its pharmacological effects by selectively inhibiting the activity of Janus kinase (JAK) enzymes, particularly JAK1 and JAK2. By inhibiting JAK enzymes, Ruxonib interferes with signaling pathways involved in inflammation and immune response, thereby reducing the symptoms associated with atopic dermatitis, such as redness, itching, and skin lesions.
3. Dosage and Administration:
The recommended dosage of Ruxonib (Ruxolitinib) 1.5% may vary depending on the severity of the skin condition and individual patient characteristics. Typically, a thin layer of Ruxonib cream should be applied topically to the affected areas of the skin twice daily. Treatment should continue until improvement of symptoms is observed, and then the frequency of application may be adjusted as directed by the healthcare provider.
4. Interaction:
Ruxonib (Ruxolitinib) 1.5% applied topically is less likely to interact with other medications compared to systemic formulations. However, patients should still inform their healthcare provider about all medications they are taking, including prescription, over-the-counter, and herbal products, to avoid potential interactions.
5. Side Effects:
Common side effects associated with Ruxonib (Ruxolitinib) 1.5% topical cream may include:
Patients should report any persistent or severe side effects to their healthcare provider for further evaluation and management.
6. Precautions and Warnings:
Before using Ruxonib (Ruxolitinib) 1.5% topical cream, patients should be aware of the following precautions:
7. Overdose Effects:
There is limited information available regarding the potential effects of overdose with topical Ruxonib (Ruxolitinib) 1.5% cream. In case of accidental ingestion or excessive topical application leading to adverse reactions, supportive care should be initiated, and symptomatic treatment may be administered as necessary. Patients should seek medical attention if significant systemic absorption or adverse effects are suspected.
Generic Name: | Ruxolitinib INN 1.5% |
---|---|
Theraputic Category: | Janus Kinase Inhibitor |
Pack Size: | 1's |
Previous Product
Next Product
Begin your journey to better health . Join now to unlock exclusive tips and insights sent straight to your inbox, empowering you to embrace a healthier lifestyle each and every day.
Online Medicine Pharmacy
+8801929123476 emedicarepharma@gmail.com
65, mymansingh High-way, Dhaka-1230, Bangladesh